Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20884954 | 0.94 | AKR1C3 (0.58) | AKR1C3MAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL23544874 | 0.87 | MAPT (0.64) | AKR1C3MAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL23544870 | 0.86 | KDM4E (0.56) | MAPTSMN1; SMN2MAPK1HTTKDM4E | |
| SCHEMBL25839451 | 0.85 | MAPT (0.53) | MAPTSMN1; SMN2MAPK1HTTKDM4E | |
| SCHEMBL27089708 | 0.84 | ME2 (0.52) | AKR1C3MAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL14923975 | 0.84 | SMN1; SMN2 (0.52) | AKR1C3MAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL20884943 | 0.84 | SMN1; SMN2 (0.55) | AKR1C3MAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL17306132 | 0.82 | PANK3 (0.56) | AKR1C3MAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL25839446 | 0.82 | SMN1; SMN2 (0.51) | AKR1C3MAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL188832 | 0.82 | AKR1C3 (0.65) | AKR1C3MAPTSMN1; SMN2MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-01-17 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | AKR1C3 4037/4885MAPT 2232/4885SMN1; SMN2 2291/4885 |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | AKR1C3 4354/4885MAPT 2828/4885SMN1; SMN2 3453/4885 |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | AKR1C3 4037/4885MAPT 2232/4885SMN1; SMN2 2291/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | AKR1C3 4037/4885MAPT 2232/4885SMN1; SMN2 2291/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | AKR1C3 4037/4885MAPT 2232/4885SMN1; SMN2 2291/4885 |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | AKR1C3 4037/4885MAPT 2232/4885SMN1; SMN2 2291/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | AKR1C3 4037/4885MAPT 2232/4885SMN1; SMN2 2291/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | AKR1C3 4210/4885MAPT 2825/4885SMN1; SMN2 3653/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | AKR1C3 4210/4885MAPT 2825/4885SMN1; SMN2 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.